NCT00851929 - Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

April 30, 2011

Study Completion Date

November 30, 2011

Conditions

SarcoidosisPulmonary Hypertension

Interventions

DRUG

Ambrisentan

ambrisentan 5 mg/day for month month, then 10 mg/day for 3 additional months

Trial Locations (2)

Medical Univerrsity of South Carolina, Charleston

University of North Carolina Medical Center, Chapel Hill